Analyse Telo Genomics Corp. (TELO.V) — Kairos Score 50/100

À propos de Telo Genomics Corp.

Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability, identify specific disease mechanisms, predict disease risks, and determine effective treatments. Its lead product is TeloView-SMM (Smoldering Multiple Myeloma) for SMM patients with a high risk of transition to multiple myeloma (MM). The company also develops TeloView NDMM, which predicts newly diagnosed MM patients who may relapse on first-line therapy; TeloMRD-D, which identifies and enumerates MRD cells in post-transplant patients; and TeloViewNG-MRD (Minimal Residual Disease) Profiling for genomic instability profiling of MRD-detected cells in post-transplant patients. It has a collaboration agreement with the Mayo Clinic. Telo Genomics Corp. is headquartered in Toronto, Canada.

Informations clés

🕴️ Activité des initiés (90 jours)

0 transactions — 0 achats et 0 ventes déclarés par les dirigeants de Telo Genomics Corp..

🏦 Hedge Funds

0 fonds institutionnels déclarent une position sur TELO.V dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

10 articles récents sur TELO.V.

• Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing
• Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.